264 related articles for article (PubMed ID: 28961714)
1. Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.
Cornely OA; Robertson MN; Haider S; Grigg A; Geddes M; Aoun M; Heinz WJ; Raad I; Schanz U; Meyer RG; Hammond SP; Mullane KM; Ostermann H; Ullmann AJ; Zimmerli S; Van Iersel MLPS; Hepler DA; Waskin H; Kartsonis NA; Maertens J
J Antimicrob Chemother; 2017 Dec; 72(12):3406-3413. PubMed ID: 28961714
[TBL] [Abstract][Full Text] [Related]
2. Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.
Cornely OA; Duarte RF; Haider S; Chandrasekar P; Helfgott D; Jiménez JL; Candoni A; Raad I; Laverdiere M; Langston A; Kartsonis N; Van Iersel M; Connelly N; Waskin H
J Antimicrob Chemother; 2016 Mar; 71(3):718-26. PubMed ID: 26612870
[TBL] [Abstract][Full Text] [Related]
3. Phase 1b/3 Pharmacokinetics and Safety Study of Intravenous Posaconazole in Adult Asian Participants at High Risk for Invasive Fungal Infections.
Wu D; Mi Y; Weng J; Zhuang J; Ke X; Wang C; Liu K; Martinho M; Winchell GA; Zang Y; Xu L
Adv Ther; 2022 Apr; 39(4):1697-1710. PubMed ID: 35167031
[TBL] [Abstract][Full Text] [Related]
4. Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience.
Jeong W; Haywood P; Shanmuganathan N; Lindsay J; Urbancic K; Ananda-Rajah MR; Chen SC; Bajel A; Ritchie D; Grigg A; Seymour JF; Peleg AY; Kong DC; Slavin MA
J Antimicrob Chemother; 2016 Dec; 71(12):3540-3547. PubMed ID: 27521358
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and Safety of Posaconazole Tablet Formulation in Chinese Participants at High Risk for Invasive Fungal Infection.
Liu K; Wu D; Li J; Chen H; Ning H; Zhao T; Dai H; Chen L; Mangin E; Winchell GA; Waskin H; Jiang J; Qiu Y; Zhao XM
Adv Ther; 2020 May; 37(5):2493-2506. PubMed ID: 32319040
[TBL] [Abstract][Full Text] [Related]
6. A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia.
Arrieta AC; Sung L; Bradley JS; Zwaan CM; Gates D; Waskin H; Carmelitano P; Groll AH; Lehrnbecher T; Mangin E; Joshi A; Kartsonis NA; Walsh TJ; Paschke A
PLoS One; 2019; 14(3):e0212837. PubMed ID: 30913226
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and safety of posaconazole intravenous solution and powder for oral suspension in children with neutropenia: an open-label, sequential dose-escalation trial.
Groll AH; Abdel-Azim H; Lehrnbecher T; Steinbach WJ; Paschke A; Mangin E; Winchell GA; Waskin H; Bruno CJ
Int J Antimicrob Agents; 2020 Sep; 56(3):106084. PubMed ID: 32682946
[TBL] [Abstract][Full Text] [Related]
8. Posaconazole prophylaxis in neutropenic patients with hematological malignancies: limits in clinical practice.
Bourdelin M; Grenouillet F; Daguindau E; Muret P; Desbrosses Y; Dubut J; Deconinck E; Limat S; Larosa F
Med Mycol; 2014 Oct; 52(7):728-35. PubMed ID: 25012993
[TBL] [Abstract][Full Text] [Related]
9. Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease.
Maertens J; Cornely OA; Ullmann AJ; Heinz WJ; Krishna G; Patino H; Caceres M; Kartsonis N; Waskin H; Robertson MN
Antimicrob Agents Chemother; 2014 Jul; 58(7):3610-7. PubMed ID: 24733463
[TBL] [Abstract][Full Text] [Related]
10. Micafungin versus posaconazole prophylaxis in acute leukemia or myelodysplastic syndrome: A randomized study.
Epstein DJ; Seo SK; Huang YT; Park JH; Klimek VM; Berman E; Tallman MS; Frattini MG; Papanicolaou GA
J Infect; 2018 Sep; 77(3):227-234. PubMed ID: 29746955
[TBL] [Abstract][Full Text] [Related]
11. Primary prophylaxis of invasive fungal infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing intensive cytotoxic chemotherapy: A real-world comparison.
Tormo M; Pérez-Martínez A; Calabuig M; Hernández-Boluda JC; Amat P; Navarro D; Solano C
Mycoses; 2018 Mar; 61(3):206-212. PubMed ID: 29125660
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.
Krishna G; AbuTarif M; Xuan F; Martinho M; Angulo D; Cornely OA
Pharmacotherapy; 2008 Oct; 28(10):1223-32. PubMed ID: 18823218
[TBL] [Abstract][Full Text] [Related]
13. Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies.
Hachem R; Assaf A; Numan Y; Shah P; Jiang Y; Chaftari AM; Raad II
Int J Antimicrob Agents; 2017 Sep; 50(3):384-388. PubMed ID: 28694233
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease.
Krishna G; Martinho M; Chandrasekar P; Ullmann AJ; Patino H
Pharmacotherapy; 2007 Dec; 27(12):1627-36. PubMed ID: 18041883
[TBL] [Abstract][Full Text] [Related]
15. Retrospective analysis of goal drug level attainment of posaconazole for invasive fungal infection prophylaxis in patients with acute myeloid leukemia pre- and post-switch to tablet formulation.
Liebenstein TK; Widmer KM; Fallon MJ
J Oncol Pharm Pract; 2018 Dec; 24(8):599-603. PubMed ID: 28768441
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and Safety of Posaconazole Administered by Intravenous Solution and Oral Tablet in Healthy Chinese Subjects and Effect of Food on Tablet Bioavailability.
Li H; Wei Y; Zhang S; Xu L; Jiang J; Qiu Y; Mangin E; Zhao XM; Xie S
Clin Drug Investig; 2019 Nov; 39(11):1109-1116. PubMed ID: 31432392
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation.
Döring M; Cabanillas Stanchi KM; Queudeville M; Feucht J; Blaeschke F; Schlegel P; Feuchtinger T; Lang P; Müller I; Handgretinger R; Heinz WJ
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1281-1292. PubMed ID: 28258343
[TBL] [Abstract][Full Text] [Related]
18. Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia.
Duarte RF; López-Jiménez J; Cornely OA; Laverdiere M; Helfgott D; Haider S; Chandrasekar P; Langston A; Perfect J; Ma L; van Iersel ML; Connelly N; Kartsonis N; Waskin H
Antimicrob Agents Chemother; 2014 Oct; 58(10):5758-65. PubMed ID: 25049247
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of antifungal prophylaxis with oral suspension posaconazole during induction chemotherapy of acute myeloid leukemia.
Schrenk KG; Schnetzke U; Stegemann K; von Lilienfeld-Toal M; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2015 Sep; 141(9):1661-8. PubMed ID: 25800622
[TBL] [Abstract][Full Text] [Related]
20. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial.
Maertens JA; Rahav G; Lee DG; Ponce-de-León A; Ramírez Sánchez IC; Klimko N; Sonet A; Haider S; Diego Vélez J; Raad I; Koh LP; Karthaus M; Zhou J; Ben-Ami R; Motyl MR; Han S; Grandhi A; Waskin H;
Lancet; 2021 Feb; 397(10273):499-509. PubMed ID: 33549194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
